替雷利珠单抗联合安罗替尼治疗晚期非小细胞肺癌的临床研究

Clinical Research of Terrezolizumab Combined with Anlotinib in Treatment of Advanced Non-Small Cell Lung Cancer

目的探讨分析替雷利珠单抗联合安罗替尼治疗晚期非小细胞肺癌的临床研究。方法研究选择在2020年6月至2022年7月于福建医科大学附属漳州市医院接受治疗的84例晚期非小细胞肺癌患者签订为本次研究的最终探究目标,按照电脑软件既定程序完成人员的选择,小组的划分按照标准执行,有42例接受安罗替尼治疗的对照组,和42例在前组治疗的基础上联合使用替雷丽珠单抗完成治疗的观察组,根据最终所得结果对比分析。结果观察组疾病控制率、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)以及NK水平均高于对照组(P<0.05)。治疗后观察组肿瘤标志物水平各项指标水平、CD8^(+)水平、各血清相关细胞因子指标水平均低于对照组(P<0.05)。两组出现不良反应的概率无差异(P>0.05)。结论处于晚期阶段的非小细胞肺癌患者,使用替雷丽珠单抗联合安罗替尼治疗,能使得患者获得更理想的临床控制率,患者最终得到的成效与理想状态更为相贴,对于肿瘤新生血管的产生起到了良好的阻碍作用,减少血清肿瘤标志物的水平大小,让患者能以更高质量的状态完成各项生活活动。

Objective To explore and analyze the clinical effect of tirelizumab combined with arotinib in treatment of advanced non-small cell lung cancer.Methods The study selected 84 cases of advanced non-small cell lung cancer patients treated in Zhangzhou Hospital of Fujian Medical University from June 2020 to July 2022 as the final target of the study,the selection of personnel was done according to the established procedures of the computer software,and the division of the group was carried out in accordance with the standard implementation of a total of 42 cases of the control group treated with amilotinib and a total of 42 cases of the observation group that completed the treatment with the use of tiralizumab in conjunction with the treatment of the former group,and the analysis was made according to the comparison of the results obtained in the final analysis.Results The disease control rate,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and NK levels of the observation group were higher than those of the control group(P<0.05).The levels of various indicators of tumor marker levels,CD8^(+)levels,and the levels of various serum-related cytokine indicators in the observation group were lower than those in the control group after treatment(P<0.05).There was no difference in the probability of adverse reactions between the two groups(P>0.05).Conclusions In the advanced stage of non-small cell lung cancer patients,the use of tirilizumab combined with anilotinib treatment,can make the patient to obtain a more ideal clinical control rate,the patient ultimately get the results of the ideal state more closely,for the production of tumor neovascularization play a good role in impeding the reduction of serum tumor markers level size,so that the patient can be in a higher quality of state to complete a variety of life activities.